CLAIMS

1. An immunocompetent cell expressing a T cell receptor specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19.

2. The immunocompetent cell according to claim 1, wherein the immunocompetent cell contains a nucleic acid encoding IL-7 introduced from outside of the cell and a nucleic acid encoding CCL19 introduced from outside of the cell.

3. The immunocompetent cell according to claim 1 or 2, wherein the immunocompetent cell is a T cell.

4. The immunocompetent cell according to any one of claims 1 to 3, wherein the cancer antigen is WT1, MART-1, NY-ESO-1, MAGE-A1, MAGE-A3, MAGE-A4, Glypican-3, KIF20A, Survivin, AFP-1, gp100, MUC1, PAP-10, PAP-5, TRP2-1, SART-1, VEGFR1, VEGFR2, NEIL3, MPHOSPH1, DEPDC1, FOXM1, CDH3, TTK, TOMM34, URLC10, KOC1, UBE2T, TOPK, ECT2, MESOTHELIN, NKG2D, P1A, GD2, or GM2.

5. An expression vector for generating the immunocompetent cell according to any one of claims 1 to 4, being any of the following (a) to (e):
(a) an expression vector containing a nucleic acid encoding a T cell receptor specifically recognizing a cancer antigen, a nucleic acid encoding IL-7, and a nucleic acid encoding CCL19;
(b) the following two expression vectors (b-1) and (b-2):

(b-1) an expression vector containing a nucleic acid encoding a T cell receptor specifically recognizing a cancer antigen; and

(b-2) an expression vector containing a nucleic acid encoding IL-7 and a nucleic acid encoding CCL19;

(c) the following two expression vectors (c-1) and (c-2):

(c-1) an expression vector containing a nucleic acid encoding a T cell receptor specifically recognizing a cancer antigen, and a nucleic acid encoding IL-7; and

(c-2) an expression vector containing a nucleic acid encoding CCL19;

(d) the following two expression vectors (d-1) and (d-2):

(d-1) an expression vector containing a nucleic acid encoding IL-7; and

(d-2) an expression vector containing a nucleic acid encoding a T cell receptor specifically recognizing a cancer antigen, and a nucleic acid encoding CCL19; and

(e) the following three expression vectors (e-1), (e-2) and (e-3):

(e-1) an expression vector containing a nucleic acid encoding a T cell receptor specifically recognizing a cancer antigen;

(e-2) an expression vector containing a nucleic acid encoding IL-7; and

(e-3) an expression vector containing a nucleic acid encoding CCL19.

6. The expression vector according to claim 5, wherein the nucleic acid encoding a T cell receptor specifically

recognizing a cancer antigen, the nucleic acid encoding IL-7, and the nucleic acid encoding CCL19 in the expression vector (a); or
the nucleic acid encoding IL-7 and the nucleic acid encoding CCL19 in the expression vector (b-2); or
the nucleic acid encoding a T cell receptor specifically recognizing a cancer antigen, and the nucleic acid encoding IL-7 in the expression vector (c-1); or
the nucleic acid encoding a T cell receptor specifically recognizing a cancer antigen, and the nucleic acid encoding CCL19 in the expression vector (d-2)
are linked via a sequence encoding a self-cleaving peptide.

7. The expression vector according to claim 5 or 6, wherein the expression vector contains a nucleic acid encoding a suicide gene.

8. An anticancer agent comprising the immunocompetent cell according to any one of claims 1 to 4 and a pharmaceutically acceptable additive.